Preview Mode Links will not work in preview mode

Oncology Overdrive

Nov 19, 2020

Julie Gralow, MD, is a well-respected and internationally renowned breast oncologist. In this episode, Gralow discusses her journey in oncology, the ASCO Global Oncology Task Force and the importance of finding your own way in medicine.

  • Intro :14
  • About Gralow :27
  • The interview 1:49
  • What has been your journey to become the very well-respected internationally renowned breast oncologist you are today? 2:21
  • How did you find yourself in that aspect of the field and also marry in your interest in mobile oncology? 4:31
  • Were there times where you faced barriers you weren’t going to be able to overcome? 13:13
  • How did you feel and what did you think when you led the ASCO Global Oncology Task Force? 16:15
  • What are some of the high points that came out of the ASCO Global Oncology Task Force report? 19:20
  • Did you focus on how the COVID-19 pandemic affected oncology management in this task force or in any of your global oncology work? 26:30
  • Did you find that social media was a useful tool throughout the last 9-10 months navigating the pandemic? 30:11
  • Realizing the benefits of social media as a medical professional and avoiding “doom scrolling” 34:00
  • Do you have one pearl for the audience? 41:47
  • How to find Julie Gralow 43:11
  • Where does Gralow see her future career going? 44:22


Julie Gralow, MD is the Jill Bennett Endowed professor of Breast Medical Oncology and professor of global health at the University of Washington School of Medicine, professor in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, and director of Breast Medical Oncology at the Seattle Cancer Care Alliance.

We’d love to hear from you! Send your comments/questions to Dr. Jain at Julie Gralow can be reached on Twitter @jrgralow and by email at Follow us on Twitter @HemOncToday @ShikhaJainMD.

Disclosures: Jain reports she is a paid freelance writer for Lippincott. Gralow reports no relevant financial disclosures.